Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vicks Sinex Severe Cold & Flu is an over-the-counter (OTC) multi-symptom medication developed by Vicks (a brand of Procter & Gamble) to alleviate symptoms associated with the common cold, influenza, and sinusitis. The formulation is typically delivered as oral LiquiCaps and contains a combination of active ingredients: acetaminophen, dextromethorphan hydrobromide, guaifenesin, and phenylephrine hydrochloride. Acetaminophen acts as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. Dextromethorphan hydrobromide is an antitussive that suppresses the cough reflex by acting on the cough center in the medulla. Guaifenesin is an expectorant that reduces the viscosity of respiratory secretions, making coughs more productive. Phenylephrine hydrochloride is a nasal decongestant that stimulates alpha-1 adrenergic receptors, causing vasoconstriction in the nasal mucosa to reduce swelling and congestion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vicks Sinex Severe Cold & Flu.